Ioxaglate Meglumine and Ioxaglate Sodium
- Atc Codes:V08AB03
- CAS Codes:59018-13-2#67992-58-9
- PHARMGKB ID:59018-13-2#67992-58-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Dosage
Brand Names
Europe
Austria: Hexabrix; Belgium: Hexabrix; Bulgaria: Hexabrix; Czech Republic: Hexabrix; Finland: Hexabrix; France: Hexabrix; Germany: Hexabrix; Greece: Hexabrix; Hungary: Hexabrix; Ireland: Hexabrix; Italy: Hexabrix; Luxembourg: Hexabrix; Netherlands: Hexabrix; Portugal: Hexabrix; Spain: Hexabrix; Sweden: Hexabrix.
North America
Canada: Hexabrix; USA: Hexabrix.
Latin America
Argentina: Hexabrix.
Drug combinations
Chemistry
Ioxaglate Meglumine: C~24~H~21~I~6~N~5~O~8~ C~7~H~17~NO~5~. Mw: 1464.09. (1) Benzoic acid, 3-[[[[3-(acetylmethylamino)-2,4,6-triiodo-5-[(methylamino)carbonyl]benzoyl]amino]acetyl]amino]-5-[[(2-hydroxyethyl)amino]carbonyl]-2,4,6-triiodo-, compound with 1-deoxy-1-(methylamino)-D-glucitol (1:1); (2) N-(2-Hydroxyethyl)-2,4,6-triiodo-5-[2-[2,4,6-triiodo-3-(N-methylacetamido)-5-(methylcarbamoyl)benzamido]acetamido]isophthalamic acid, compound with 1-deoxy-1-(methylamino)-D-glucitol (1:1). CAS-59018-13-2 (1982).
Ioxaglate Sodium: C~24~H~21~I~6~N~5~O~8~. Mw: 1290.86. Benzoic acid, 3-[[[[3-(acetylmethylamino)-2,4,6-triiodo-5-[(methylamino)carbonyl]benzoyl]amino]acetyl]amino]-5-[[(2-hydroxyethyl)amino]carbonyl]-2,4,6-triiodo-, sodium salt. CAS-67992-58-9 (1982).
Pharmacologic Category
Diagnostic Agents; Imaging Agents; Iodinated Contrast Media. Radiological/Contrast Media (Ionic, Low Osmolality). (ATC-Code: V08AB03).
Mechanism of action
Therapeutic use
Angiocardiography, arteriography, aortography, arthrography, angiography, hysterosalpingography, venography, and urography procedures. Contrast enhancement of computed tomographic imaging.
Pregnancy and lactiation implications
Animal reproduction studies did not show fetal harm. In general, iodinated contrast media agents are avoided during pregnancy unless essential for diagnosis. Not recommended in nursing women.
Unlabeled use
Contraindications
Hypersensitivity to ioxaglate or any component of the formulation. Myelography. Hysterosalpingography during menstrual period, pregnancy, genital tract infection, or cervical conization or curettage within 30 days. Arthrography with infection present in or near the joint.